[1]齐 锐,王何斌,李 劲,等.原发性肝癌患者血清miR-196b 和miR-520f 表达水平及其临床诊断价值分析[J].现代检验医学杂志,2023,38(05):47-52.[doi:10.3969/j.issn.1671-7414.2023.05.009]
　QI Rui,WANG Hebin,LI Jing,et al.Expression and Clinical Diagnostic Value of Serum miR-196b and miR-520f in Primary Hepatocellular Carcinoma[J].Journal of Modern Laboratory Medicine,2023,38(05):47-52.[doi:10.3969/j.issn.1671-7414.2023.05.009]
点击复制

原发性肝癌患者血清miR-196b 和miR-520f 表达水平及其临床诊断价值分析()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第38卷
期数:
2023年05期
页码:
47-52
栏目:
论著
出版日期:
2023-09-15

文章信息/Info

Title:
Expression and Clinical Diagnostic Value of Serum miR-196b and miR-520f in Primary Hepatocellular Carcinoma
文章编号:
1671-7414（2023）05-047-06
作者:
齐 锐; 王何斌; 李 劲; 杨茂辉; 徐 杰
（攀枝花学院附属医院肝胆科，四川攀枝花 617000）
Author(s):
QI Rui; WANG Hebin; LI Jing; YANG Maohui; XU Jie
（Department of Hepatology, Affiliated Hospital of Panzhihua University, Sichuan Panzhihua 617000, China）
关键词:
原发性肝癌; 微小核糖核酸-196b; 微小核糖核酸-520f
分类号:
R735.7；R730.43
DOI:
10.3969/j.issn.1671-7414.2023.05.009
文献标志码:
A
摘要:
目的 探讨原发性肝癌(primary carcinoma of the liver) 患者血清微小核糖核酸（microRNA，miR）-196b，微小核糖核酸（microRNA，miR）-520f 表达水平及其临床诊断价值。方法 选择2020 年6 月～ 2022 年6 月攀枝花学院附属医院收治的73 例原发性肝癌患者作为研究组，患者均符合《原发性肝癌诊疗规范》中的诊断标准；选择同期医院体检的80 例健康人群作为对照组。抽取研究对象清晨空腹外周静脉血5ml，采用实时荧光定量逆转录- 聚合酶链反应（real time fluorescent quantitative reverse transcription-polymerase chain reaction，qRT-PCR）检测两组血清miR-196b 和miR-520f 表达水平。分析不同临床病理特征原发性肝癌患者血清miR-196b 和miR-520f 表达水平差异，采用Pearson相关性分析探讨血清miR-196b 与miR-520f 的关系，采用受试者工作特征（receiver operating characteristic ，ROC）曲线分析血清miR-196b 和miR-520f 对原发性肝癌的诊断价值。结果 研究组血清miR-196b 表达水平（2.73±0.56）明显高于对照组（0.99±0.24），miR-520f 表达水平（1.69±0.44）明显低于对照组（3.34±0.64），差异具有统学意义（t=30.578，12.690，均P<0.05）。与Ⅰ～Ⅱ期、中高分化、无淋巴结转移、肿瘤直径<5cm 患者相比，Ⅲ～Ⅳ期、低分化、淋巴结转移和肿瘤直径≥ 5cm 患者血清miR-196b 表达水平均升高，miR-520f 表达水平均降低，差异具有统计学意义（tmiR-196b=6.919 ～ 13.229，tmiR-520f=3.873 ～ 7.814，均P<0.05）。Pearson 相关性分析显示，原发性肝癌患者血清miR-196b 表达水平与miR-520f 表达水平呈负相关（r=-0.445，P=0.006）。ROC 曲线分析显示，血清miR-196b 预测原发性肝癌的曲线下面积、截断值、敏感度、特异度及95% 置信区间（95% confidence interval，95%CI）分别为0.842，2.55，91.78%，62.50% 和95%CI（0.810 ～ 0.874）；miR-520f 预测原发性肝癌的的曲线下面积、截断值、敏感度、特异度及95% 置信区间分别为0.872，2.43，91.78%，67.50% 和95%CI（0.848 ～ 0.906）；血清miR-196b 联合miR-520f 预测原发性肝癌的曲线下面积、敏感度、特异度及95% 置信区间分别为0.923，86.30%，87.50% 和95%CI（0.891 ～ 0.955）。结论 原发性肝癌患者血清miR-196b 表达水平上调，miR-520f 表达水平下调，其表达水平变化与肿瘤直径、临床分期、分化程度和淋巴结转移密切相关，联合检测血清miR-196b 与miR-520f 能有效提高原发性肝癌的诊断效能。
Abstract:
Objective To explore the expression level and diagnostic value of serum microRNA (miR) -196b and microRNA- (miR) -520f in primary hepatocellular carcinoma. Methods Seventy-three patients with primary hepatocellular carcinoma who met the criteria in Diagnosis, Management, and Treatment of Hepatocellular Carcinoma in the Affiliated Hospital of Panzhihua University from June 2020 to June 2022 were enrolled as study group. Meantime, another 80 healthy individuals underwent physical examination during the same period were set as control group. Milliliters (5ml) of fasting venous blood samples were obtained from all subjects. Expression levels of miR-196b and miR-520f in serum were detected by real-time fluorescence quantitative reverse transcription polymerase chain reaction (qRT-PCR). The two indicators were compared among primary hepatocellular carcinoma patients with different clinicopathological characteristics. Thereafter, the Pearson correlation analysis was conducted to discuss the correlation between serum miR-196b and miR-520f expression, and receiver operating characteristic (ROC) curve was plotted to evaluate the value of serum miR-196b and miR-520f in primary hepatocellular carcinoma. Results Serum miR-196b expression level was 2.73±0.56 in study group, which was higher than in control group(0.99±0.24) ，and miR-520f expression level was 1.69±0.44 in study group, which was lower than in control group(3.34±0.64)，and the differences were statistically significant (t=30.578，12.690, P<0.05). Compared with patients with stage III ～ IV, low differentiation, lymph node metastasis, and tumor diameter ≥ 5 cm detected higher serum miR-196b expression levels and lower miR-520f expression compared with those with stage I ～ II, moderate-to-high differentiation, no lymph node metastasis, and tumor diameter <5 cm, respectively，and the differences were statistically significant（tmiR-196b=4.868 ～ 13.229, tmiR- 520f=3.873 ～ 7.814, all P<0.05）.Pearson correlation analysis denoted that the miR-196b expression level in serum of patients with primary hepatocellular carcinoma was negatively correlated with the miR-520f expression level (r=-0.445, P=0.006). In the prediction of primary hepatocellular carcinoma, ROC curve analysis suggested that the area under the curve, cut-off value, sensitivity，specificity and 95% confidence interval（95%CI）were 0.842，2.55，91.78%，62.50%，and 95%CI (0.810~0.874) for serum miR-196b, and those were 0.872, 2.43, 91.78%, 67.50% , and [95%CI(0.848 ～ 0.906)]for serum miR-520f, while the combined detection of the two indicators showed better predictive efficacy, with area under the curve, sensitivity，specificity and 95%CI of 0.923，86.30%，87.50%，and 95%CI [95%CI(0.891 ～ 0.955)],respectively. Conclusion Patients with primary hepatocellular carcinoma have up-regulated miR-196b expression and down-regulated miR-520f in serum, and the two abnormal changes are closely correlated with the tumor diameter, clinical stage, differentiation degree, and lymph node metastasis in patients. Furthermore, the combined detection of two indicators is of great value in the diagnosis of primary hepatocellular carcinoma.

参考文献/References:

[1] XIA Changfa, DONG Xuesi, LI He, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chinese Medical Journal, 2022, 135(5): 584-590.
[2] 莫嘉浩, 方彩珊, 许洪彬, 等. 基于信使核糖核酸和微型核糖核酸芯片分析进展期肝癌靶基因[J]. 中国临床药理学杂志, 2020, 36( 13): 1837-1841. MO Jiahao, FANG Caishan, XU Hongbin, et al. Target genes for advanced hepatocellular carcinoma based on messenger RNA and microRNA chips[J]. Chinese Journal of Clinical Pharmacology, 2020, 36(13): 1837-1841.
[3] 马智, 曹男, 李昶. 血清miR-122, miR-33a 水平在老年原发性肝癌患者中的意义及其对TACE 治疗预后的影响[J]. 国际检验医学杂志, 2022, 43( 9): 1106-1110. MA Zhi, CAO Nan, LI Chang. Significance of serum miR-122 and miR-33a levels in elderly patients with primary liver cancer and their influence on prognosis after TACE [J]. International Journal of Laboratory Medicine, 2022, 43(9): 1106-1110.
[4] GAMLEN H A, ROMER-SEIBERT J S, LAWLER M E, et al. MiR-196b-TLR7/8 signaling axis regulates innate immune signaling and myeloid maturation in DNMT3A-mutant AML[J]. Clinical Cancer Research,2022, 28(20): 4574-4586.
[5] DIOGUARDI M, CANTORE S, SOVERETO D, et al. Potential role of miR-196a and miR-196b as prognostic biomarkers of survival in head and neck squamous cell carcinoma: a systematic review, meta-analysis and trial sequential analysis[J]. Life Basel Switzerland, 2022, 12(8): 1269.
[6] SUN Mingxia, AN Qun, CHEN Lamei, et al. MiR-520f regulated itch expression and promoted cell proliferation in human melanoma cells[J]. Dose-Response, 2020, 18(2): 1559325820918450.
[7] ZHOU Yingyan, SHEN Shimo. MiR-520f acts as a biomarker for the diagnosis of lung cancer[J].Medicine(Baltimore), 2019, 98(30): e16546.
[8] 中华人民共和国卫生和计划生育委员会医政医管局. 原发性肝癌诊疗规范(2017 年版) [J] . 中华消化外科杂志,2017,16 (7): 635-647. Bureau of Medical Administration, National Health and Family Planning Comission of the People’s Republic of China. Standardization of diagnosis and treatment for hepatocellular carcinoma (2017 edition) [J]. Chinese Journal of Digestive Surgery, 2017, 16(7): 635-647.
[9] 程松, 郭婧澜. 血清miR-21, miR-148b, miR-200a,miR-200 b 在原发性肝癌患者中的表达及临床诊断意义[J]. 中国老年学杂志, 2020, 40( 5): 951-955. CHENG Song, GUO Jinglan. Expressions of serum miR-21, miR-148b, miR-200a and miR-200b in patients with primary liver cancer and their clinical significance[J]. Chinese Journal of Gerontology, 2020, 40(5): 951-955.
[10] 董顺玲. 在原发性肝癌临床诊断中检测甲胎蛋白、癌胚抗原、糖原199 及糖原125 指标的准确性分析[J]. 黑龙江医学, 2022, 46( 2): 147-148, 152. DONG Shunling. Accuracy analysis of detection of AFP, CEA, CA199 and CA125 in the clinical diagnosis of primary liver cancer [J]. Heilongjiang Medical Journal, 2022, 46(2): 147-148, 152.
[11] 刘雯, 沙银中, 李亚东. 循环microRNA 在常见肿瘤中的应用研究进展[J]. 国际检验医学杂志, 2018,39(16): 1950-1954. LIU Wen, SHA Yinzhong, LI Yadong. Advances in the application of circulating micrornas in common tumors[J]. International Journal of Laboratory Medicine, 2018, 39(16): 1950-1954.
[12] 袁冲, 赵征, 廖子君, 等. 血清miR-122 和miR-570联合检测对原发性肝癌的临床诊断价值[J]. 现代肿瘤医学, 2021, 29( 2): 267-270. YUAN Chong, ZHAO Zheng, LIAO Zijun, et al. The clinical diagnostic value of serum miR-122 and miR-570 combined detection in primary hepatic carcinoma[J]. Journal of Modern Oncology, 2021, 29(2): 267-270.
[13] 车佳, 黄兰兰, 娄琼, 等. 利用TCGA 数据库分析miR-196b 在结直肠癌患者中的临床表达特征并探索miR-196b 的体外抗5-FU 作用[J]. 中国病理生理杂志, 2018, 34( 1): 152-157. CHE Jia, HUANG Lanlan, LOU Qiong, et al. Analyzing clinical characteristic of miR-196b in human colorectal cancer using TCGA and effect of miR-196b on 5-FU resistance of CRC cell line [J]. Chinese Journal of Pathophysiology, 2018, 34(1): 152-157.
[14] 彭艳艳, 李聪, 张欣宇. 非小细胞肺癌组织中miR-92a, miR-196b 表达水平及其临床意义[J]. 实用癌症杂志, 2021, 36( 9): 1421-1425. PENG Yanyan, LI Cong, ZHANG Xinyu. Expression levels and clinical significance of miR-92a and miR-196b in non-small cell lung cancer tissues [J]. Practical Journal of Cancer, 2021, 36(9): 1421-1425.
[15] 张玉清, 邢惠海, 刘立秋, 等. miR-196b 调控PI3K/Akt 通路对宫颈癌细胞顺铂耐药的影响研究[J]. 中国免疫学杂志, 2021, 37( 23): 2865-2870. ZHANG Yuqing, XING Huihai, LIU Liqiu, et al. Effect of miR-196b on cisplatin resistance of cervical cancer cells by regulating PI3K/Akt pathway [J]. Journal of Clinical Hepatology, 2021, 37(23): 2865-2870.
[16] 肖二辉, 宁会彬, 康月花, 等. 下调miR-196b 靶向核凋亡诱导因子1 调控肝癌细胞生长和凋亡的机制[J]. 临床肝胆病杂志, 2020, 36( 10): 2230-2235. XIAO Erhui, NING Huibin, KANG Yuehua, et al. Downregulation of miR-196b in regulating the growth and apoptosis of hepatoma cells by targeting nuclear apoptosis-inducing factor 1 [J]. Journal of Clinical Hepatology, 2020, 36(10): 2230-2235.
[17] 陶正贵, 杜静虎, 田葵, 等. miR-520f-3p 靶向MCL1抑制结肠癌细胞生长及移植瘤发生[J]. 中国老年学杂志, 2022, 42( 14): 3526-3532. TAO Zhenggui, DU Jinghu, TIAN Kui, et al. MiR-520f-3p targets MCL1 to inhibit the growth of colon cancer cells and xenograft tumorigenesis[J]. Chinese Journal of Gerontology, 2022, 42(14): 3526-3532.
[18] 张玲玲, 张小霞, 於潇潇, 等. 非小细胞肺癌患者血浆miR-520f,miR-143-3p 表达与病理特征和预后的相关性研究[J]. 现代检验医学杂志, 2022, 37( 3): 69-72, 78. ZHANG Lingling, ZHANG Xiaoxia, YU Xiaoxiao, et al. Correlation study on plasma miR-520f and miR-143-3p expression with pathological features and prognosis in patients with non-small cell lung cancer [J]. Journal of Modern Laboratory Medicine, 2022, 37(3): 69-72, 78.
[19] XU Fengfeng, XIE Wenfeng, ZHA Guoqing, et al. MiR-520f promotes cell aggressiveness by regulating fibroblast growth factor 16 in hepatocellular carcinoma[J].Oncotarget, 2017, 8(65): 109546-109558.
[20] 苗春木, 龚建平, 熊彬, 等. microRNA-196b，microRNA-217 与TGFβR1 蛋白在胰腺导管腺癌组织中的表达及其意义[J]. 中国普外基础与临床杂志,2018, 25(9): 1077-1082. MIAO Chunmu, GONG Jianping, XIONG Bin, et al. The expressions of microRNA-196b, microRNA-217, and TGFβR1 protein in the pancreatic ductal adenocarcinoma tissues [J]. Chinese Journal of Bases and Clinics in General Surgery, 2018, 25(9): 1077-1082.
[21] CUI Jinggang, LI Wei, LIU Guohua, et al. A novel circular RNA,hsa_circ_0043278,acts as a potential biomarker and promotes non-small cell lung cancer cell proliferation and migration by regulating miR-520f[J].Artificial Cells, Nanomedicine, and Biotechnology (Print), 2019, 47(1): 810-821.
[22] 范婧怡, 王健. 胰腺导管腺癌组织miR-196b，TGFβR1 表达变化及其意义[J]. 山东医药, 2021,61( 10): 53-56. FAN Jingyi, WANG Jian. Expression of miR-196b and TGF βR 1 in pancreatic ductal adenocarcinoma and its significance[J]. Shandong Medical Journal, 2021, 61(10): 53-56.
[23] DU Xiaoqin, FAN Wanhu, CHEN Yunru. MicroRNA-520f inhibits hepatocellular carcinoma cell proliferation and invasion by targeting TM4SF1J]. Gene, 2018,657:30-38.

相似文献/References:

[1]卓传尚,柳丽娟,周淑燕.AFP-L3和PIVKA-Ⅱ检测对高危人群良恶性肝病的鉴别诊断价值[J].现代检验医学杂志,2017,32(04):40.[doi:10.3969/j.issn.1671-7414.2017.04.011]
　ZHUO Chuan-shang,LIU Li-juan,ZHOU Shu-yan.Performance of Serum AFP-L3 and PIVKA-Ⅱ in Differential Diagnosis of Benign and Malignant Liver Disease in High Risk Population[J].Journal of Modern Laboratory Medicine,2017,32(05):40.[doi:10.3969/j.issn.1671-7414.2017.04.011]
[2]赵清侠,许丽荣,杨 莹,等.原发性肝癌患者血清VEGF浓度与抑郁症发生的相关性研究[J].现代检验医学杂志,2017,32(06):96.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　ZHAO Qing-xia,XU Li-rong,YANG Ying,et al.Study on the Correlation between Serum VEGF Concentration and Major Depressive Disorder of Patients with Primary Liver Cancer[J].Journal of Modern Laboratory Medicine,2017,32(05):96.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[3]刘国振,陈秀余,张修欢.血清 miR-122-5p，miR-486-5p，AFP及 AFP-L3水平联合检测对原发性肝癌的诊断价值[J].现代检验医学杂志,2022,37(01):82.[doi:10.3969/j.issn.1671-7414.2022.01.017]
　LIU Guo-zhen,CHEN Xiu-yu,ZHANG Xiu-huan.Value of Combined Detection of Serum miR-122-5p, miR-486-5p, AFP and AFP-L3 Levels in the Diagnosis of Primary LiverCancer[J].Journal of Modern Laboratory Medicine,2022,37(05):82.[doi:10.3969/j.issn.1671-7414.2022.01.017]
[4]邢文静a,卢相琴,齐敬聪b,等.血清高尔基体糖蛋白73与MIF水平联合检测对原发性肝癌的诊断和预后价值研究[J].现代检验医学杂志,2022,37(02):66.[doi:10.3969/j.issn.1671-7414.2022.02.014]
　XING Wen-jinga,LU Xiang-qin,QI Jing-congb,et al.Study on the Diagnostic and Prognostic Value of Serum Golgiglycoprotein 73 Combined with MIF Level in Primary Liver Cancer[J].Journal of Modern Laboratory Medicine,2022,37(05):66.[doi:10.3969/j.issn.1671-7414.2022.02.014]

备注/Memo

备注/Memo:
基金项目：国家重大疑难病中西医临床协作试点项目。
作者简介：齐锐（1986-），男，本科，主任医师，研究肝胆胰脾疾病方面，E-mail:l183804251@163.com。
通讯作者：王何斌（1972-），男，本科，主任医师，研究肝胆胰脾疾病方面。
更新日期/Last Update: 2023-09-15